1. Home
  2. GCTK vs ADTX Comparison

GCTK vs ADTX Comparison

Compare GCTK & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GlucoTrack Inc.

GCTK

GlucoTrack Inc.

HOLD

Current Price

$0.74

Market Cap

1.3M

Sector

Health Care

ML Signal

HOLD

Logo Aditxt Inc.

ADTX

Aditxt Inc.

HOLD

Current Price

$0.42

Market Cap

641.6K

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCTK
ADTX
Founded
2001
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3M
641.6K
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
GCTK
ADTX
Price
$0.74
$0.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.2M
574.5K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.32
EPS
31.22
N/A
Revenue
$589,462.00
$3,195.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.05
52 Week High
$15.90
$7.13

Technical Indicators

Market Signals
Indicator
GCTK
ADTX
Relative Strength Index (RSI) 37.58 36.74
Support Level $0.62 $0.41
Resistance Level $1.67 $1.13
Average True Range (ATR) 0.17 0.12
MACD 0.03 -0.05
Stochastic Oscillator 13.42 3.95

Price Performance

Historical Comparison
GCTK
ADTX

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.

About ADTX Aditxt Inc.

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.

Share on Social Networks: